Publications by authors named "Kris Todd"
Clin Pharmacol Drug Dev
October 2024
Article Synopsis
- The study aimed to test the safety, tolerability, and pharmacokinetics of mirikizumab in 60 healthy Chinese adults, who were divided into five dosing groups receiving either the drug or a placebo.
- No serious side effects or deaths occurred; mild treatment-emergent adverse events (TEAEs) were reported in 56% of participants receiving the drug, compared to 80% in the placebo group.
- The pharmacokinetic results showed that higher IV doses led to a 3.5-fold increase in drug concentration metrics, while subcutaneous doses increased by 1.6-fold, with the drug remaining in the system for about 10 days.
